Emily A Anderson

US Patent:

8252755, Aug 28, 2012

Filed:

Sep 20, 2007

Appl. No.:

11/858829

Inventors:

Christina Yamada - Boulder CO, US
Anastasia Khvorova - Boulder CO, US
Rob Kaiser - Broomfield CO, US
Emily Anderson - Lafayette CO, US
Devin Leake - Denver CO, US

Assignee:

Dharmacon, Inc. - Lafayette CO

International Classification:

A61K 48/00

US Classification:

514 44, 536 245, 536 2431, 536 241

Abstract:

Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.

US Patent:

8501706, Aug 6, 2013

Filed:

Jul 19, 2012

Appl. No.:

13/552709

Inventors:

Christina Yamada - Boulder CO, US
Anastasia Khvorova - Northborough MA, US
Rob Kaiser - Broomfield CO, US
Emily Anderson - Lafayette CO, US
Devin Leake - Denver CO, US

Assignee:

Dharmacon, Inc. - Lafayette CO

International Classification:

C12N 15/11

US Classification:

514 44A

Abstract:

Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.

US Patent:

20070218495, Sep 20, 2007

Filed:

Mar 15, 2007

Appl. No.:

11/724346

Inventors:

Amanda Birmingham - Lafayette CO, US
Emily Anderson - Lafayette CO, US
Angela Reynolds - Conifer CO, US
Devin Leake - Denver CO, US
Scott Baskerville - Louisville CO, US
Yuriy Fedorov - Superior CO, US
Jon Karpilow - Boulder CO, US
William Marshall - Boulder CO, US
Anastasia Khvorova - Boulder CO, US

Assignee:

Dharmacon, Inc. - Lafayette CO

International Classification:

C40B 40/08
C07H 21/02

US Classification:

435 6, 536 231

Abstract:

The present invention provides methods, libraries and computer program products for selecting siRNA that reduce off-target effects and methods for gene silencing using these siRNAs. By comparing nucleotide sequences at positions 2-7 or 2-8 of the sense and/or antisense regions of candidate siRNAs to the 3′ UTR region of mRNAs, one can select siRNAs that have reduced off-target effects.

US Patent:

20070269889, Nov 22, 2007

Filed:

Feb 4, 2005

Appl. No.:

11/051195

Inventors:

Devin Leake - Denver CO, US
Anastasia Khvorova - Boulder CO, US
Yuriy Fedorov - Superior CO, US
Michael Delaney - Firestone CO, US
Barbara Robertson - Boulder CO, US
Emily Anderson - Lafayette CO, US
Angela Reynolds - Conifer CO, US

Assignee:

DHARMACON, INC. - Lafayette CO

International Classification:

C07H 21/04

US Classification:

435375000, 536024100

Abstract:

RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5′ terminal sense nucleotides with 2′-O-alkyl groups and a label on the first 5′ terminal sense nucleotide, in conjunction with at least one additional 2′-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2′ fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5′ terminal antisense nucleotide; or (ii) a first and second 5′ terminal antisense nucleotide with 2′-O-alkyl modifications and at least one additional 2′-O-alkyl pyrimidine modified antisense nucleotide.

US Patent:

20080009012, Jan 10, 2008

Filed:

Jul 6, 2007

Appl. No.:

11/825461

Inventors:

Amanda Birmingham - Lafayette CO, US
Emily Anderson - Lafayette CO, US
Angela Reynolds - Conifer CO, US
Devin Leake - Denver CO, US
Scott Baskerville - Louisville CO, US
Yuriy Fedorov - Superior CO, US
Jon Karpilow - Boulder CO, US
William Marshall - Boulder CO, US
Anastasia Khvorova - Boulder CO, US

Assignee:

DHARMACON, INC. - Lafayette CO

International Classification:

C12Q 1/68
C07H 21/04

US Classification:

435006000, 536024500

Abstract:

The present disclosure provides methods, libraries and computer program products for determining whether a phenotype induced by a candidate siRNA for a target gene in an RNAi experiment is target specific or a false positive. Through the use of a control siRNA that has one or two seed sequences of six or seven bases in combination with a neutral scaffolding sequence, a distinction can be made between false positive and true positive analyses of functionality.

US Patent:

20090280567, Nov 12, 2009

Filed:

Jun 17, 2009

Appl. No.:

12/486497

Inventors:

Devin Leake - Denver CO, US
Anastasia Khvorova - Boulder CO, US
Yuriy Fedorov - Superior CO, US
Michael Owen Delaney - Dacono CO, US
Barbara Robertson - Boulder CO, US
Emily Anderson - Lafayette CO, US
Angela Reynolds - Conifer CO, US

Assignee:

DHARMACON, INC. - Lafayette CO

International Classification:

C12N 15/87
C07H 21/02

US Classification:

435440, 536 241

Abstract:

RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5′ terminal sense nucleotides with 2′-O-alkyl groups and a label on the first 5′ terminal sense nucleotide, in conjunction with at least one additional 2′-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2′ fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5′ terminal antisense nucleotide; or (ii) a first and second 5′ terminal antisense nucleotide with 2′-O-alkyl modifications and at least one additional 2′-O-alkyl pyrimidine modified antisense nucleotide.

US Patent:

20100093085, Apr 15, 2010

Filed:

Sep 20, 2007

Appl. No.:

12/442278

Inventors:

Christina Yamada - Boulder CO, US
Anastasia Khvorova - Boulder CO, US
Rob Kaiser - Broomfield CO, US
Emily Anderson - Lafayette CO, US
Devin Leake - Denver CO, US

Assignee:

DHARMACON, INC - LAFAYETTE CO

International Classification:

C12N 5/00
C07H 21/04

US Classification:

435375, 536 231

Abstract:

Provided herein are tripartite oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene. The tripartite oligonucleotide complexes of the disclosure may include a conjugate moiety that facilitates delivery to a cell, tissue or organism without the aid of a transfection reagent

US Patent:

20110160285, Jun 30, 2011

Filed:

Mar 12, 2009

Appl. No.:

12/921827

Inventors:

Emily Anderson - Lafayette CO, US
Anastasia Khvorova - Northborough MA, US
Anita G. Seto - Golden CO, US
Scott Baskerville - Louisville CO, US
Leslie Leinwand - Boulder CO, US
Kevin G. Sullivan - Boulder CO, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
Dharmacon, Inc. - Lafayette CO

International Classification:

A61K 31/7105
C40B 30/04
A61P 9/00

US Classification:

514 44 A, 506 9

Abstract:

Disclosed herein are a collection of miRNAs and genes whose expression is altered in hypertrophic cardiomyopathy. Accordingly, these miRNAs and genes, singly or in combination, are useful as molecular markers for diagnosis or prognosis of hypertrophic cardiomyopathy. The miRNAs and genes disclosed can also be therapeutic targets for cardiac hypertrophy. For example, agents such as miRNA mimics, miRNA inhibitors or siRNAs for a given miRNA or gene can be used to modulate the level of these molecules thereby inhibiting or preventing hypertrophic cardiomyopathy.